LIGAND PHARMACEUTICALS INCORPORATED Deferred Income Tax Expense (Benefit)
LIGAND PHARMACEUTICALS INCORPORATED (LGND) reported Deferred Income Tax Expense (Benefit) of $21.89 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-02-27
- LIGAND PHARMACEUTICALS INCORPORATED deferred income tax expense (benefit) for fiscal 2025 was $21.89M.
- LIGAND PHARMACEUTICALS INCORPORATED deferred income tax expense (benefit) for fiscal 2024 was -$15.80M, a 257.54% decline from fiscal 2023.
- LIGAND PHARMACEUTICALS INCORPORATED deferred income tax expense (benefit) for fiscal 2023 was $10.03M, a 67.11% decline from fiscal 2022.
- LIGAND PHARMACEUTICALS INCORPORATED deferred income tax expense (benefit) for fiscal 2022 was $30.49M.
| Period end | Deferred Income Tax Expense (Benefit) 12 month | Deferred Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2025-12-31 | $21.89M 10-K · filed 2026-02-27 | |
| 2024-12-31 | -$15.80M 10-K · filed 2026-02-27 | |
| 2023-12-31 | $10.03M 10-K · filed 2026-02-27 | |
| 2022-12-31 | $30.49M 10-K · filed 2025-02-28 | |
| 2021-12-31 | -$4.59M 10-K · filed 2024-02-29 | -$8.62M 10-K · filed 2022-02-28 |
| 2020-12-31 | -$16.69M 10-K · filed 2023-02-28 | -$19.05M 10-K · filed 2022-02-28 |
| 2019-12-31 | $74.83M 10-K · filed 2022-02-28 |